
Please try another search
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Kan Chen | 43 | 2020 | Independent Non-Executive Director |
Barry D. Quart | 68 | 2024 | CEO & Director |
Kleanthis G. Xanthopoulos | 67 | 2020 | Independent Chairman |
Stuart J. Swiedler | 68 | 2021 | Member of Scientific Advisory Board |
Edward M. Kerwin | - | 2021 | Member of Scientific Advisory Board |
Jean I. Liu | 57 | 2021 | Independent Director |
David T. Rubin | - | 2021 | Member of Scientific Advisory Board |
John V. Fahy | - | 2021 | Member of Scientific Advisory Board |
Brian Gordon Feagan | - | 2021 | Member of Scientific Advisory Board |
Zuie-Chin Huang | 59 | 2024 | Independent Director |
Karen J. Wilson | 62 | 2020 | Independent Non-Executive Director |
Emma Guttman-Yassky | - | 2021 | Member of Scientific Advisory Board |
Jonathan Silverberg | - | 2023 | Member of Scientific Advisory Board |
James A. Schoeneck | 67 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review